Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;206(3):266-281.
doi: 10.1111/cei.13641. Epub 2021 Jul 18.

Clinical and neuroimaging findings in MOGAD-MRI and OCT

Affiliations
Review

Clinical and neuroimaging findings in MOGAD-MRI and OCT

Frederik Bartels et al. Clin Exp Immunol. 2021 Dec.

Abstract

Myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are rare in both children and adults, and have been recently suggested to be an autoimmune neuroinflammatory group of disorders that are different from aquaporin-4 autoantibody-associated neuromyelitis optica spectrum disorder and from classic multiple sclerosis. In-vivo imaging of the MOGAD patient central nervous system has shown some distinguishing features when evaluating magnetic resonance imaging of the brain, spinal cord and optic nerves, as well as retinal imaging using optical coherence tomography. In this review, we discuss key clinical and neuroimaging characteristics of paediatric and adult MOGAD. We describe how these imaging techniques may be used to study this group of disorders and discuss how image analysis methods have led to recent insights for consideration in future studies.

Keywords: magnetic resonance imaging; myelin oligodendrocyte glycoprotein associated disorders; optical coherence tomography.

PubMed Disclaimer

Conflict of interest statement

F. Bartels is supported by the Berlin Institute of Health (BIH) and the Berlin School of Mind and Brain, both unrelated to this review. A. Lu has no disclosures to report. F. C. Oertel receives research support from the American Academy of Neurology (AAN) unrelated to this review. C. Finke receives research funding by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; grant numbers FI 2309/1‐1 and FI 2309/2‐1) and the German Ministry of Education and Research (BMBF, grant number 01GM1908D; CONNECT‐GENERATE) unrelated to this review. F. Paul is named as co‐inventor on the patent application for the foveal shape analysis method (‘Method for estimating shape parameters of the fovea byoptical coherence tomography’, International Publication number: ‘WO 2019/016319 A1’), is a co‐founder and holds shares in technology start‐up Nocturne GmbH, receives honoraria for lecturing and travel expenses for attending meetings from Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe and Celgene. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Alexion, Roche, Parexel and Almirall. C. Chien has received speaking fees from Bayer and research support from Novartis unrelated to this review.

Figures

FIGURE 1
FIGURE 1
Cerebral magnetic resonance imaging (MRI) in paediatric myelin oligodendrocyte glycoprotein‐associated disorders (MOGAD). (a,b) Axial T2‐weighted fluid‐attenuated inversion recovery (FLAIR) MRI sequences of a 3‐year‐old female MOG‐immunoglobulin (Ig)G‐positive acute disseminated encephalomyelitis (ADEM) patient showing bilateral white matter and deep grey matter thalamic lesions. (c) Axial T2‐weighted MRI sequence of a 12‐year‐old female patient with MOG‐immunoglobulin (Ig)G‐positive ADEM and bilateral optic neuritis (ON) showing optic nerve swelling and hyperintensity
FIGURE 2
FIGURE 2
Spinal cord magnetic resonance imaging (MRI) in paediatric myelin oligodendrocyte glycoprotein associated disorders (MOGAD). Sagittal (a) and transversal (b) T2‐weighted spinal cord MRI of a 12‐year‐old female patient with MOG‐immunoglobulin (Ig)G‐positive acute disseminated encephalomyelitis (ADEM). (b) Longitudinally extensive transverse myelitis (LETM) with grey matter spinal cord affection presenting with the ‘H‐sign’ and (a) as longitudinal hyperintense line. (c) Sagittal T2‐weighted cervical cord MRI in a 3‐year‐old female patient with MOG‐IgG‐seropositive ADEM (the same patient shown in Figure 1a,b)
FIGURE 3
FIGURE 3
Adult myelin oligodendrocyte glycoprotein‐associated disorders (MOGAD) patient cerebral and spinal cord affection. (a) T2‐weighted fluid‐attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) sequence in the axial orientation showing large, confluent hyperintense lesions in the white matter. (b) In the coronal view of the same cerebral scan as in (a), it can be seen that the lesions extend toward the cortex. (c) The T2‐weighted spinal cord MRI shows short segment lesions, appearing to be located centrally in the cord
FIGURE 4
FIGURE 4
Retinal anatomy and optical coherence tomography. (a) Anatomical representation of the human retina and (b) the human retina as imaged using optical coherence tomography (OCT). These images have been kindly reproduced and modified under a Creative Common Licence from www.neurodial.de. RNFL = retinal nerve fibre layer; GCL = ganglion cell layer; IPL = inner plexiform layer; GCIP = ganglion cell and inner plexiform layer
FIGURE 5
FIGURE 5
Macular scans from optical coherence tomography (OCT). Macular scans of various retinas with corresponding thickness scale (0–150 µm) with heat‐maps highlighting the thickness variations across the macular ganglion cell and inner plexiform (GCIP) layer. (a) Variations in the thickness across various pathologies in different patients. (b) Right eye of the same myelin oligodendrocyte glycoprotein‐associated disorders (MOGAD) patient prior to optic neuritis (ON) after two and four ONs. Thinner areas are depicted with cooler colours (purple/blue) and thicker areas depicted with warmer colours (red/yellow). HC = healthy control; MOGAD‐NON: MOGAD with no history of ON; AQP‐4‐IgG: aquaporin‐4 immunoglobulin G

References

    1. Zamvil SS, Slavin AJ. Does MOG Ig‐positive AQP4‐seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm. 2015;2:e62. - PMC - PubMed
    1. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15:89–102. - PubMed
    1. Reindl M, Schanda K, Woodhall M, Tea F, Ramanathan S, Sagen J, et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm. 2020;7:e674. - PMC - PubMed
    1. Wegener‐Panzer A, Cleaveland R, Wendel E‐M, Baumann M, Bertolini A, Häusler M, et al. Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies. Neurol ‐ Neuroimmunol Neuroinflamm. 2020;7:e731. - PMC - PubMed
    1. Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;1:66–72. - PubMed

Publication types

MeSH terms